AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie adjusted After-Tax Earnings — Non-GAAP ($M) ($M)
Form 8-K Non-GAAP Reconciliations
Latest, FY2025
17,784
Period ended Dec 31, 2025
Change on a year earlier
-1.2%
18,001 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Adjusted After-Tax Earnings — Non-GAAP ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 17,784 | -1.2% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 18,001 | -8.9% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 19,769 | -19.6% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 24,597 | – | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
Breakdown
What makes up adjusted after-tax earnings — non-gaap ($m)
- Reported After-Tax Earnings — GAAP ($M)4,226 · FY2025
- Adjusted Pre-Tax Earnings — Non-GAAP ($M)21,692 · FY2025
- Reported Pre-Tax Earnings — GAAP ($M)6,597 · FY2025
- Adjusted Cost of Products Sold — Non-GAAP ($M)21,692 · FY2025
- Adjusted SG&A Expense — Non-GAAP ($M)3,901 · FY2025
- Adjusted Income Tax Expense — Non-GAAP ($M)3,901 · FY2025
Cite this data
StockData. (2026). AbbVie Adjusted After-Tax Earnings — Non-GAAP ($M) ($M), annual FY2022–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/nongaap_adj_aftertax
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.